Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health, Inc. (NASDAQ:JAGX) has submitted the final technical section required by the FDA to seek approval for its oral plant-based drug, Canalevia, aimed at treating chemotherapy-induced diarrhea in dogs. With over 50,000 dogs affected annually, Canalevia would be the first FDA-approved medicine for this condition. The company anticipates conditional approval for both chemotherapy-induced and exercise-induced diarrhea by mid-2021. Jaguar’s subsidiary, Napo Pharmaceuticals, markets Mytesi, another crofelemer-based product for humans.
Jaguar Health (NASDAQ:JAGX) has submitted the final technical section to the FDA for approval of Canalevia, a plant-based drug to treat chemotherapy-induced diarrhea (CID) in dogs. This submission marks a significant step towards potentially becoming the first FDA-approved treatment for over 50,000 affected dogs annually. The filing supports conditional approval under the Minor Use/Minor Species Act. Jaguar also plans to seek approval for treating exercise-induced diarrhea. Canalevia aims to improve comfort and chemotherapy tolerance in dogs.
Jaguar Health (NASDAQ:JAGX) announced an amendment to its accounts receivable purchase agreement with Oasis Capital, LLC. This agreement involves the purchase of additional accounts receivable worth $3,152,545 related to Mytesi drug sales. Oasis will pay $1,339,831.83, with a fee of 5.45% on the total amount. The company aims to secure non-dilutive capital to enhance its cash flow. Mytesi is approved for treating noninfectious diarrhea in HIV/AIDS patients.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a second amendment to its accounts receivable purchase agreement with Oasis Capital for the purchase of additional accounts receivable valued at $3,152,545 related to the sales of Mytesi drug product. Following this amendment, the Company will receive $1,339,831.83 after Oasis charges a 5.45% fee. The financing aims to support Jaguar's strategy to secure non-dilutive capital and work towards becoming a cash flow positive business.
Jaguar Health reported significant growth in Mytesi sales for Q2 2020, with net sales reaching approximately $3.2 million, a 186% increase from $1.7 million in Q2 2019. Gross sales also saw a substantial rise, hitting about $6.3 million, reflecting 268% growth year-over-year. Loss from operations decreased to $8.45 million, improved by lower operating expenses and increased product pricing. Meanwhile, net loss significantly reduced by 45% to $9.24 million. A virtual disease education event is scheduled for October 20, 2020, to discuss cancer therapy-related diarrhea.
Jaguar Health reported significant growth in Q2 2020, with Mytesi net sales reaching approximately $3.2 million, up 186% from Q2 2019. Gross sales were about $6.3 million, marking a 268% increase year-over-year. The company also reported a 45% reduction in net loss to $9.2 million, driven by higher Mytesi prices and decreased operating losses. Expenses fell 6% year-over-year. Total Mytesi bottles sold rose 104.3% compared to the same period last year. Despite these gains, the company continues to navigate operating losses.
Jaguar Health (NASDAQ:JAGX) announced plans to file its Q2 2020 10-Q on August 13, 2020. The company will host a conference call the same day at 8:30 a.m. ET to discuss financial results and updates. Investors can participate via a toll-free number or a live webcast on the company's website. Additionally, a virtual disease awareness event, Diarrhea Dialogues, is scheduled for October 20, 2020, focusing on cancer therapy-related diarrhea, featuring expert discussions on supportive care. Further details will be shared closer to the event date.
Jaguar Health, Inc. (NASDAQ:JAGX) will hold a conference call on August 13, 2020, at 8:30 a.m. ET to discuss Q2 2020 financials.
The company is also planning a virtual disease awareness event titled Diarrhea Dialogues on October 20, 2020, focusing on cancer therapy-related diarrhea, featuring leading oncologists and patient advocates. For more details on the investor call and event registration, visit the company's website.